Categories AlphaGraphs, Earnings, Health Care

Eli Lilly (LLY) reports Q1 2020 earnings results

Adjusts EPS guidance amid COVID19 pandemic

Pharmaceutical company Eli Lilly (NYSE: LLY) reported first quarter 2020 revenue of $5.86 billion, up 15% year-over-year.

Amid COVID-19 pandemic, the company saw increased customer buying patterns and prescription trends which resulted in revenue increase of approx. $250 million for the quarter.

Net income was $1.457 billion or $1.60 per share, compared with net income of $4.242 billion or $4.31 per in the first quarter of 2019.

Josh Smiley, CFO commented on the outlook:

“Our revenue and operating margin outlook for 2020 is unchanged, but the economic and healthcare consequences of this pandemic are uncertain and could negatively affect our financial results later in 2020 and beyond, due to reduced non-COVID healthcare activities and global economic challenges. We are therefore widening the range of our 2020 EPS guidance to reflect both our underlying strong performance as well as future uncertainty; however, the long-term fundamentals of our business remain strong, as does our financial outlook for the mid-2020s and beyond.”

Eli Lilly Reports Strong First-Quarter Financial Results, Adjusts EPS Guidance

Past Performance

Also Read:  Alphabet (GOOG/GOOGL) Q2 2020 earnings: The most important numbers

Most Popular

Baidu (BIDU) Q2 earnings rise unexpectedly; stock falls

https://www.youtube.com/watch?v=50yUaLybUnA&t=667s China-based internet search firm Baidu Inc. (NASDAQ: BIDU) reported financial results for the second quarter of 2020 on Thursday after the market's close. Earnings exceeded analysts’ expectations, but the

Applied Materials (AMAT) tops Q3 2020 targets; provides Q4 outlook

Applied Materials' (NASDAQ: AMAT) earnings and revenue for the third quarter exceeded the market's views. Adjusted EPS of $1.06 and revenue of $4.40 billion in Q3, grew 43% and 23%,

Is Altimmune (ALT) stock a buy right now?

A lot of stocks in the biotech space have skyrocketed this year after their announcements and advances in finding a vaccine or in the treatment of COVID-19. While these companies

Top